Editing Cabergoline (section)

===Off-label===
Cabergoline has at times been used as an adjunct to [[SSRI]] [[antidepressants]] as there is some evidence that it counteracts certain [[adverse effect|side effects]] of those [[drugs]], such as reduced [[libido]] and [[anorgasmia]]. It also has been suggested that it has a possible [[recreational]] use in reducing or eliminating the male [[refractory period (sex)|refractory period]], thereby  allowing men to experience multiple ejaculatory orgasms in rapid succession, and at least two scientific studies support those speculations.<ref>{{cite journal | vauthors = Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, Leygraf N, Hartmann U, Schedlowski M | title = Effects of acute prolactin manipulation on sexual drive and function in males | journal = The Journal of Endocrinology | volume = 179 | issue = 3 | pages = 357–365 | date = December 2003 | pmid = 14656205 | doi = 10.1677/joe.0.1790357 | citeseerx = 10.1.1.484.4005 }}</ref><ref>{{cite journal | vauthors = Hollander AB, Pastuszak AW, Hsieh TC, Johnson WG, Scovell JM, Mai CK, Lipshultz LI | title = Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | journal = Sexual Medicine | volume = 4 | issue = 1 | pages = e28–e33 | date = March 2016 | pmid = 26944776 | pmc = 4822480 | doi = 10.1016/j.esxm.2015.09.001 }}</ref>{{rp|e28–e33}} Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of [[ovarian hyperstimulation syndrome]] (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of [[in vitro fertilization]] (IVF).<ref>{{cite journal | vauthors = Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, van der Veen F | title = Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis | journal = Human Reproduction Update | volume = 16 | issue = 5 | pages = 459–466 | date = March 2010 | pmid = 20354100 | doi = 10.1093/humupd/dmq006 | doi-access = free }}</ref> Also, a study on rats found that cabergoline reduces voluntary alcohol consumption, possibly by increasing [[GDNF]] expression in the [[ventral tegmental area]].<ref>{{cite journal | vauthors = Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D | title = Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor | journal = Biological Psychiatry | volume = 66 | issue = 2 | pages = 146–153 | date = July 2009 | pmid = 19232578 | pmc = 2895406 | doi = 10.1016/j.biopsych.2008.12.022 }}</ref> It may be used in the treatment of [[restless legs syndrome]].{{Citation needed|date=April 2021}}. Oral administration of cabergoline was faced with gastrointestinal problems which cause poor compliance in patients. One of the preferred solutions is to use non-oral dosage forms like suppositories. Vaginal suppositories have ease of use and could hinder gastrointestinal effects of cabergoline.<ref>{{cite journal | vauthors = Rahmanian-Devin P, Fadaei MR, Mashreghi M, Askari VR | title = Preparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline | journal = Saudi Pharmaceutical Journal | volume = 31 | issue = 12 | pages = 101849 | date = December 2023 | pmid = 38028218 | pmc = 10663909 | doi = 10.1016/j.jsps.2023.101849 }}</ref>